|

Neoadjuvant Pembrolizumab Clinical Trials

2 actively recruiting trials across 2 locations

No change since May 2026

Pipeline

Phase 2: 2

Top Sponsors

  • University of Texas Southwestern Medical Center1
  • UNC Lineberger Comprehensive Cancer Center1

Indications

  • Cancer2
  • Node-positive Breast Cancer1
  • Renal Cell Carcinoma1
  • HER2-Negative Breast Carcinoma1
  • Triple Negative Breast Cancer (TNBC)1

Chapel Hill, North Carolina1 trial

Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer

University of North Carolina

Phase 2

Dallas, Texas1 trial

Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

University of Texas Southwestern Medical Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.